Drug intelligence / Profile preview

VRT001-C

Development stage: Preclinical
Lead developer: Venus Remedies
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

VRT001-C is an oral formulation of the third-generation cephalosporin antibiotic ceftriaxone, developed by Venus Remedies (specifically through its research wing, Venus Medicine Research Centre) using its proprietary Stealth Targeted Nanoparticles (STN) platform technology. The STN platform is designed to overcome the poor oral bioavailability of ceftriaxone (which is typically administered intravenously) by creating a pH-sensitive, stealth-targeted nanoparticle matrix that enhances gastrointestinal absorption. VRT001-C is being developed for the treatment of bacterial infections, particularly those associated with antimicrobial resistance (AMR), providing an oral alternative to intravenous antibiotic therapy.

Other names: oral ceftriaxone

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on VRT001-C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRT001-C.